Extra - Revision history

John at 18:53, 13 June 2023

2023-06-13T18:53:40Z

← Older revision		Revision as of 20:53, 13 June 2023
Line 42:		Line 42:
	! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')		! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')
	\|-		\|-
	~~\|style="width: 14.25%; background: #006699; color:white"\|40-80%~~
	~~\|style="width: 12.5%; background: #004466; color:white"\|80-100%~~
	~~\|style="width: 12.5%; background: #004466; color:white"\|80-100%~~
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: #~~00b8e6~~; color:black"\|~~20-40~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: #~~00b8e6~~; color:black"\|~~20-40~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #~~004466~~; color:~~white~~"\|~~80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
			\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
			\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
			\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|-		\|-
	\|}		\|}


	<span style="font-size:90%">'''Notes:''' The main application is in AML. Aberrant expression is seen in ALL particularly in T-lineage, although it may be less likely in Burkitt lymphoma. CD117 expression can indicate MPAL or ETP-ALL if other markers are consistent.


Line 62:		Line 60:
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-
	\|style="width: 12.5%; background: #~~004466~~; color:~~white~~"\|~~80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 12.5%; background: #~~004466; color:white"\|80-100%~~		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	~~\|style="width: 12.5%; background: #66e0ff~~; color:black"\|5~~-20~~%
	\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
			\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|-		\|-
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' expression is ~~common but selective~~ in ~~mature B-lymphoproliferative disorders~~, with ~~expression being rare~~ in ~~MCL and FL~~</span>		<span style="font-size:90%">'''Notes:''' expression is usual in myeloma, and will occur on cells with plasma cell differentiation in LPL or MZL</span>


Line 91:		Line 89:
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being uncommon in T-lymphoproliferative disorders~~, but expression has been described in angioimmunoblastic lymphoma~~</span>		<span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being very uncommon in T-lymphoproliferative disorders</span>
	----		----

John at 18:48, 13 June 2023

2023-06-13T18:48:59Z

← Older revision		Revision as of 20:48, 13 June 2023
Line 5:		Line 5:
	:<span style="color:navy">'''Summary'''</span>		:<span style="color:navy">'''Summary'''</span>

	:~~CD200~~ is not ~~lineage specific being seen in a lymphoid~~ and ~~myeloid disorders but has an role~~ in ~~diagnosis: CD200~~ expression ~~aids the distinction between CLL where~~ expression is ~~consistent and mantle cell lymphoma~~ (~~MCL) where expression is rare. It is important to realise~~ that ~~CD200 is not a CLL-specific marker and is also expressed on a wide range of other neoplastic B~~ cell ~~types~~		:CD138 is a marker used to identify normal or malignant plasma cells with a high level of specificity, but does not discriminate normal from abnormal plasma cells and in some cases expression in myeloma may be low compared with normal plasma cells so sensitivity can be an issue. Abberancy of expression is low, but expression may be seen in lymphoplamacytic or marginal zone lymphomas (only on those cells that have plasma cell differentiation)


Line 14:		Line 14:
	<span style="color:navy">'''Normal expression and function'''</span>		<span style="color:navy">'''Normal expression and function'''</span>

	~~CD200~~ is a membrane ~~glycoprotein~~ that ~~braodly delivers an inhibitory signal for inflammation in diverse tissues~~. ~~CD200~~ is ~~commonly expressed on cells of hematopoietic lineage, specifically macrophages, dendritic cells, neutrophils, mast cells and eosinophils,~~ as ~~well as B cells and activated T~~ cells.		CD138 is a membrane protein that supports cell adhesion or binds cytokines and chemokines. In the hematopoietic system expression of CD138 is acquired by B lymphocytes as they develop into plasma cells.


Line 21:		Line 21:
	<span style="color:navy">'''Diagnostic role'''</span>		<span style="color:navy">'''Diagnostic role'''</span>

	*~~CD200 is consisently expressed~~ in ~~chronic lymphocytic leukemia CLL, including cases~~ with ~~atypical morphology~~ or ~~atypical expression~~ of ~~other surface markers~~		*Most often CD138 used in conjunction with CD38 to identify plasma cells in the diagnosis or monitoring of myeloma
	*~~CD200 not usually expressed by MCL~~, ~~making CD200 a particularly useful marker for discrimination between CLL and MCL. Note however that expression of MCL has been reported~~ in ~~a small number of~~ cases ~~so the distinction is not absolute~~		*There is very little aberrant expression, but neoplastic plasma cells may in some cases have weak, variable, or occasionally undetectable expression
	*CD200 is overexpressed by many different cell types and is neither lineage nor stage-specific, ~~being expressed by B-cell progenitors and nearly all precursor B lymphoblastic leukemias. It is expressed by over 70% of myelomas~~, ~~and hairy cell leukemia also exhibits a high level of staining~~		*Expression is also seen cells that have plasmacytic differentiation in lymphoplasmacytoid lymphoma or marginal zone lymphoma
	*~~expression in AML~~ is also ~~recorded~~


Line 30:		Line 29:
	<span style="color:navy">'''Other useful information'''</span>		<span style="color:navy">'''Other useful information'''</span>

	~~CD200~~ is ~~also~~ expressed ~~on endothelial neuronal cells and cells of the reproductive organs ovaries and placental trophoblasts~~.		Outside of haematopoiesis CD138 is expressed by squamous epithelium.

	----		----

John at 14:00, 13 June 2023

2023-06-13T14:00:39Z

← Older revision		Revision as of 16:00, 13 June 2023
Line 66:		Line 66:
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #~~004466~~; color:~~white~~"\|5-20%		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:black"\|5-20		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:black"\|5-20		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
	\|-		\|-

John at 13:58, 13 June 2023

2023-06-13T13:58:59Z

← Older revision		Revision as of 15:58, 13 June 2023
Line 74:		Line 74:
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' expression is ~~uncommon~~ in mature B-lymphoproliferative disorders, ~~but may occur~~ in ~~plasma cells~~</span>		<span style="font-size:90%">'''Notes:''' expression is common but selective in mature B-lymphoproliferative disorders, with expression being rare in MCL and FL</span>


Line 92:		Line 92:
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being uncommon in T-lymphoproliferative disorders, but ~~may occur~~ in ~~some cases of T-PLL~~</span>		<span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being uncommon in T-lymphoproliferative disorders, but expression has been described in angioimmunoblastic lymphoma</span>
	----		----

John at 13:54, 13 June 2023

2023-06-13T13:54:54Z

← Older revision		Revision as of 15:54, 13 June 2023
Line 63:		Line 63:
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-
			\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 12.5%; background: #004466; color:white"\|5-20%
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|5-20
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|5-20
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:~~black~~"\|~~<5%~~		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
	~~\|style="width: 12.5%; background: #00b8e6; color:black"\|20~~-40%
	\|-		\|-
	\|}		\|}

John at 13:50, 13 June 2023

2023-06-13T13:50:21Z

← Older revision		Revision as of 15:50, 13 June 2023
Line 44:		Line 44:
	\|-		\|-
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
	\|style="width: 14.25%; background: #~~006699~~; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 14.25%; background: #~~006699~~; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background: #~~006699~~; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|-		\|-
	\|}		\|}

John at 13:48, 13 June 2023

2023-06-13T13:48:08Z

← Older revision		Revision as of 15:48, 13 June 2023
Line 5:		Line 5:
	:<span style="color:navy">'''Summary'''</span>		:<span style="color:navy">'''Summary'''</span>

	:~~CD117~~ is ~~a widely expressed molecule that~~ in ~~haematology is used most often as~~ a ~~marker of primitive~~ myeloid ~~cells~~ where ~~it contributes to a diagnosis of AML. However~~ expression is ~~absent in around 20-30% of typical AML~~ and ~~there is recognised aberrant expression by up to 30% of ALL cases~~ (~~more frequently in T lineage~~). ~~CD117~~ is also expressed ~~by mast cells, and weakly~~ on ~~some plasma cells~~		:CD200 is not lineage specific being seen in a lymphoid and myeloid disorders but has an role in diagnosis: CD200 expression aids the distinction between CLL where expression is consistent and mantle cell lymphoma (MCL) where expression is rare. It is important to realise that CD200 is not a CLL-specific marker and is also expressed on a wide range of other neoplastic B cell types


Line 14:		Line 14:
	<span style="color:navy">'''Normal expression and function'''</span>		<span style="color:navy">'''Normal expression and function'''</span>

	~~CD117 was originally described~~ in ~~1987 as c-kit (the cellular homolog~~ of ~~the feline sarcoma viral oncogene v-kit). Stem cell factor (SCF) binds to CD117 initiating signals that variously control apoptosis~~, ~~differentiation~~, ~~proliferation~~, ~~chemotaxis or cellular adhesion. In myeloid~~ cells, ~~CD117 is expressed by early haematopoietic progenitor~~ cells ~~then expression is lost as the~~ cells ~~mature~~.		CD200 is a membrane glycoprotein that braodly delivers an inhibitory signal for inflammation in diverse tissues. CD200 is commonly expressed on cells of hematopoietic lineage, specifically macrophages, dendritic cells, neutrophils, mast cells and eosinophils, as well as B cells and activated T cells.


Line 21:		Line 21:
	<span style="color:navy">'''Diagnostic role'''</span>		<span style="color:navy">'''Diagnostic role'''</span>

	*~~In acute myeloid leukaemia expression of CD117~~ is ~~seen~~ in ~~70-80% of cases~~ including ~~less differentiated forms, it may be expression by any subtype, but is less likely in~~ cases with ~~monocytic, erythroid,~~ or ~~megakaryocytic maturation~~		*CD200 is consisently expressed in chronic lymphocytic leukemia CLL, including cases with atypical morphology or atypical expression of other surface markers
	*~~Aberrant~~ expression ~~in acute lymphoid leukaemias is~~ reported ~~- more frequently~~ in ~~T-lineage ALL (particularly more primitive types). Expression in B-lineage ALL~~ is ~~less frequent.~~		*CD200 not usually expressed by MCL, making CD200 a particularly useful marker for discrimination between CLL and MCL. Note however that expression of MCL has been reported in a small number of cases so the distinction is not absolute
	~~Expression~~ by ~~mature B cell or mature T~~ cell types is ~~rare~~, ~~although CD117 expression is described on some CD8 positive mature T~~ cell ~~neoplasms~~. Around 30 of ~~myeloma cases express CD117~~, ~~but often~~ expression is ~~weak which limits its value in this disorder~~		*CD200 is overexpressed by many different cell types and is neither lineage nor stage-specific, being expressed by B-cell progenitors and nearly all precursor B lymphoblastic leukemias. It is expressed by over 70% of myelomas, and hairy cell leukemia also exhibits a high level of staining
	*CD117 can be used to identify mast cells, but does not distinguish normal from neoplastic cells.		*expression in AML is also recorded


Line 30:		Line 30:
	<span style="color:navy">'''Other useful information'''</span>		<span style="color:navy">'''Other useful information'''</span>

	~~Outside of the haematopoietic system CD117 has a wide expression that includes germ~~ cells~~, cajal~~ cells of the ~~gastrointestinal tract~~ and epithelial cells in skin and breast. Gain-of-function mutations are seen in tumours affecting mast cells, myeloid cells, systemic mastocytosis, acute myeloid leukemia or cajal cells gastrointestinal stromal tumors - GOST tumours.		CD200 is also expressed on endothelial neuronal cells and cells of the reproductive organs ovaries and placental trophoblasts.

	----		----
Line 44:		Line 44:
	\|-		\|-
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
	\|style="width: 14.25%; background:#~~66e0ff~~; color:~~black~~"\|5-20%		\|style="width: 14.25%; background: #006699; color:white"\|80-100%
	\|style="width: 14.25%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 14.25%; background: #006699; color:white"\|80-100%
	\|style="width: 14.25%; background:#~~66e0ff~~; color:black"\|5~~-20%~~		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	~~\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40~~%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%
			\|style="width: 14.25%; background: #006699; color:white"\|80-100%
	\|-		\|-
	\|}		\|}

John at 10:41, 12 June 2023

2023-06-12T10:41:15Z

← Older revision		Revision as of 12:41, 12 June 2023
Line 75:		Line 75:

	<span style="font-size:90%">'''Notes:''' expression is uncommon in mature B-lymphoproliferative disorders, but may occur in plasma cells</span>		<span style="font-size:90%">'''Notes:''' expression is uncommon in mature B-lymphoproliferative disorders, but may occur in plasma cells</span>

	~~<span style="font-size:90%"> Additional note [[PLL]] and [[vHCL]] are no longer included, click on the name for further information</span>~~


Line 94:		Line 92:
	\|}		\|}

			<span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being uncommon in T-lymphoproliferative disorders, but may occur in some cases of T-PLL</span>
	----		----

John at 10:38, 12 June 2023

2023-06-12T10:38:47Z

← Older revision		Revision as of 12:38, 12 June 2023
Line 39:		Line 39:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 87.5%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 87.5%; height 20px;"
	\|-		\|-
	!colspan="7"\|<span style="font-size:100%">'''~~CD13 expression~~: primitive cell types''' ''Click (i) on table for additional information'' </span></font>		!colspan="7"\|<span style="font-size:100%">'''Expression: primitive cell types''' ''Click (i) on table for additional information'' </span></font>
	\|-		\|-
	! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')		! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')
Line 59:		Line 59:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-		\|-
	!colspan="8"\|'''~~CD13 expression~~: mature B cell neoplasms'''		!colspan="8"\|'''Expression: mature B cell neoplasms'''
	\|-		\|-
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
Line 82:		Line 82:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"
	\|-		\|-
	!colspan="7"\|'''~~CD13 expression~~: mature T cell neoplasms'''		!colspan="7"\|'''Expression: mature T cell neoplasms'''
	\|-		\|-
	! ATLL !! CTCL Sezary !! T-PLL !! T-LGL !! NK-LGL		! ATLL !! CTCL Sezary !! T-PLL !! T-LGL !! NK-LGL

John at 10:37, 12 June 2023

2023-06-12T10:37:54Z

← Older revision		Revision as of 12:37, 12 June 2023
Line 69:		Line 69:
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #~~00b8e6~~; color:black"\|~~20-40~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #00b8e6; color:black"\|20-40%		\|style="width: 12.5%; background: #00b8e6; color:black"\|20-40%
	\|-		\|-
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' ~~overall~~ expression is uncommon in mature B-lymphoproliferative disorders, but may occur at plasma ~~cell differentiation~~</span>		<span style="font-size:90%">'''Notes:''' expression is uncommon in mature B-lymphoproliferative disorders, but may occur in plasma cells</span>

	<span style="font-size:90%"> Additional note [[PLL]] and [[vHCL]] are no longer included, click on the name for further information</span>		<span style="font-size:90%"> Additional note [[PLL]] and [[vHCL]] are no longer included, click on the name for further information</span>

← Older revision		Revision as of 20:53, 13 June 2023
Line 42:		Line 42:
	! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')		! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')
	\|-		\|-
	~~\|style="width: 14.25%; background: #006699; color:white"\|40-80%~~
	~~\|style="width: 12.5%; background: #004466; color:white"\|80-100%~~
	~~\|style="width: 12.5%; background: #004466; color:white"\|80-100%~~
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: #~~00b8e6~~; color:black"\|~~20-40~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: #~~00b8e6~~; color:black"\|~~20-40~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #~~004466~~; color:~~white~~"\|~~80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
			\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
			\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
			\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|-		\|-
	\|}		\|}


	<span style="font-size:90%">'''Notes:''' The main application is in AML. Aberrant expression is seen in ALL particularly in T-lineage, although it may be less likely in Burkitt lymphoma. CD117 expression can indicate MPAL or ETP-ALL if other markers are consistent.


Line 62:		Line 60:
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-
	\|style="width: 12.5%; background: #~~004466~~; color:~~white~~"\|~~80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 12.5%; background: #~~004466; color:white"\|80-100%~~		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	~~\|style="width: 12.5%; background: #66e0ff~~; color:black"\|5~~-20~~%
	\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
			\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|-		\|-
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' expression is ~~common but selective~~ in ~~mature B-lymphoproliferative disorders~~, with ~~expression being rare~~ in ~~MCL and FL~~</span>		<span style="font-size:90%">'''Notes:''' expression is usual in myeloma, and will occur on cells with plasma cell differentiation in LPL or MZL</span>


Line 91:		Line 89:
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being uncommon in T-lymphoproliferative disorders~~, but expression has been described in angioimmunoblastic lymphoma~~</span>		<span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being very uncommon in T-lymphoproliferative disorders</span>
	----		----

← Older revision		Revision as of 16:00, 13 June 2023
Line 66:		Line 66:
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #~~004466~~; color:~~white~~"\|5-20%		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:black"\|5-20		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:black"\|5-20		\|style="width: 12.5%; background: #66e0ff; color:black"\|5-20%
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
	\|-		\|-

← Older revision		Revision as of 15:54, 13 June 2023
Line 63:		Line 63:
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-
			\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 12.5%; background: #004466; color:white"\|5-20%
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|5-20
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|5-20
	\|style="width: 12.5%; background: #~~E6FAFF~~; color:~~black~~"\|~~<5%~~		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
	~~\|style="width: 12.5%; background: #00b8e6; color:black"\|20~~-40%
	\|-		\|-
	\|}		\|}

← Older revision		Revision as of 15:50, 13 June 2023
Line 44:		Line 44:
	\|-		\|-
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
	\|style="width: 14.25%; background: #~~006699~~; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 14.25%; background: #~~006699~~; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background: #~~006699~~; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|-		\|-
	\|}		\|}